The global prostate cancer therapeutics market was valued at USD 19.81 billion in 2024. It is expected to grow from USD 25.12 billion in 2025 to USD 101.98 billion by 2032, demonstrating a strong compound annual growth rate (CAGR) of 22.2% over the forecast period. North America held the largest market share in 2024, accounting for 50.98%
